The US Supreme Court’s much awaited decision in mid-June that naturally occurring genes cannot be patented immediately sent waves through the market for genetic testing. Within hours, competitors of Myriad Genetics, which had held a monopoly for nearly 2 decades on genetic testing for cancer-related mutations in the tumor-suppressing genes BRCA1 and BRCA2, began offering their own versions of the test for as little as $995, about one-third of the cost of Myriad’s test.
Kuehn BM. Supreme Court Rules Against Gene Patents. JAMA. 2013;310(4):357–359. doi:10.1001/jama.2013.8627
* * SCHEDULED MAINTENANCE * *
The JAMA Network Sites will be conducting routine maintenance from 10/20/2017 through 10/21/2017. During this window access to content and authentication may be intermittently available. The JAMA Store will be completely unavailable during the maintenance window.